<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31960533</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-6924</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Risk analysis : an official publication of the Society for Risk Analysis</Title><ISOAbbreviation>Risk Anal</ISOAbbreviation></Journal><ArticleTitle>Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.</ArticleTitle><Pagination><StartPage>248</StartPage><EndPage>265</EndPage><MedlinePgn>248-265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/risa.13447</ELocationID><Abstract><AbstractText>Nearly 20 years after the year 2000 target for global wild poliovirus (WPV) eradication, live polioviruses continue to circulate with all three serotypes posing challenges for the polio endgame. We updated a global differential equation-based poliovirus transmission and stochastic risk model to include programmatic and epidemiological experience through January 2020. We used the model to explore the likely dynamics of poliovirus transmission for 2019-2023, which coincides with a new Global Polio Eradication Initiative Strategic Plan. The model stratifies the global population into 72 blocks, each containing 10 subpopulations of approximately 10.7 million people. Exported viruses go into subpopulations within the same block and within groups of blocks that represent large preferentially mixing geographical areas (e.g., continents). We assign representative World Bank income levels to the blocks along with polio immunization and transmission assumptions, which capture some of the heterogeneity across countries while still focusing on global poliovirus transmission dynamics. We also updated estimates of reintroduction risks using available evidence. The updated model characterizes transmission dynamics and resulting polio cases consistent with the evidence through 2019. Based on recent epidemiological experience and prospective immunization assumptions for the 2019-2023 Strategic Plan, the updated model does not show successful eradication of serotype 1 WPV by 2023 or successful cessation of oral poliovirus vaccine serotype 2-related viruses.</AbstractText><CopyrightInformation>Published 2020. This article is a U.S. Government work and is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cochi</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U2R GH001913</GrantID><Acronym>GH</Acronym><Agency>CGH CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Risk Anal</MedlineTA><NlmUniqueID>8109978</NlmUniqueID><ISSNLinking>0272-4332</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012308" MajorTopicYN="N">Risk Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dynamic modeling</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">polio</Keyword><Keyword MajorTopicYN="N">poliovirus vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31960533</ArticleId><ArticleId IdType="mid">NIHMS1655951</ArticleId><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="doi">10.1111/risa.13447</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, . . . Kew O. (2013). Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol, 87(9), 4907&#x2013;4922. doi:10.1128/jvi.02954-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02954-12</ArticleId><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, . . . Hartford M. (2017). Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. Journal of Infectious Diseases, 215(3), 335&#x2013;343. doi:10.1093/infdis/jiw542</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw542</ArticleId><ArticleId IdType="pmc">PMC5393058</ArticleId><ArticleId IdType="pubmed">27932608</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, &amp; Thompson KM (2016). Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation. BMC Infectious Diseases, 16, 237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, &amp; Thompson KM (2016). Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. Journal of Vaccines and Vaccination, 7(5), 340. doi:10.4172/2157-7560.1000340</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7560.1000340</ArticleId><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowsa DA, &amp; Thompson KM (2018). Poliovirus containment risks and their management. Future Virology, 13(9), 617&#x2013;628. doi:10.2217/fvl-2018-0079</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2018-0079</ArticleId><ArticleId IdType="pmc">PMC7885305</ArticleId><ArticleId IdType="pubmed">33598044</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, &amp; Thompson KM (2019). Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission. BMJ Open, 9(1), e023938. doi:10.1136/bmjopen-2018-023938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-023938</ArticleId><ArticleId IdType="pmc">PMC6340450</ArticleId><ArticleId IdType="pubmed">30647038</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, &amp; Thompson KM (2014). The potential impact of expanding target age groups for polio immunization campaigns. BMC Infectious Diseases, 14, 45. doi:10.1186/1471-2334-14-45</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-45</ArticleId><ArticleId IdType="pmc">PMC3918103</ArticleId><ArticleId IdType="pubmed">24472313</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, . . . Thompson KM (2013a). Expert review on poliovirus immunity and transmission. Risk Analysis, 33(4), 544&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896540</ArticleId><ArticleId IdType="pubmed">22804479</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, . . . Thompson KM (2013b). Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis, 33(4), 606&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890644</ArticleId><ArticleId IdType="pubmed">23550968</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, . . . Thompson KM (2011). Economic analysis of the Global Polio Eradication Initiative. Vaccine, 29(2), 334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">21029809</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, &amp; Thompson KM (2013). Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Analysis, 23(4), 703&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, C&#xe1;ceres VM, Jafari H, Cochi SL, . . . Thompson KM (2006). Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 26(6), 1471&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, . . . Thompson KM (2013). Review: Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Analysis, 23(4), 680&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, &amp; Thompson KM (2015). Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infectious Diseases, 15(379), doi:10.1186/s12879-12015-11115-12875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-12015-11115-12875</ArticleId><ArticleId IdType="pmc">PMC4574619</ArticleId><ArticleId IdType="pubmed">26382043</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, Cochi SL, &amp; Thompson KM (2015). An economic analysis of poliovirus risk management policy options for 20132052. BMC Infectious Diseases, 15(389), doi:10.1186/s12879-12015-11112-12878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-12015-11112-12878</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, &amp; Thompson KM (2016). Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infectious Diseases, 16, 137. doi:10.1186/s1287-9016-1465-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s1287-9016-1465-7</ArticleId><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2017). Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential OPV cessation risk management strategy. Epidemiology &amp; Infection, 145(2), 217&#x2013;226. doi:10.1017/S0950268816002302</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816002302</ArticleId><ArticleId IdType="pmc">PMC5197684</ArticleId><ArticleId IdType="pubmed">27760579</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2018). Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Review of Vaccines, 17(8), 739&#x2013;751. doi:10.1080/14760584.2018.1506333</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1506333</ArticleId><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson RH (1985). Vaccine preventable diseases of children. Retrieved from New York:</Citation></Reference><Reference><Citation>Henderson RH, Keja J, Hayden G, Galaka A, Clements J, &amp; Chan C. (1988). Immunizing the children of the world: progress and prospects. Bulletin of the World Health Organization, 66(5), 535&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2491189</ArticleId><ArticleId IdType="pubmed">3264762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull HF, Birmingham ME, Melgaard B, &amp; Lee JW (1997). Progress toward global polio eradication. J Infect Dis, 175 Suppl 1, S4&#x2013;9. doi:10.1093/infdis/175.supplement_1.s4</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/175.supplement_1.s4</ArticleId><ArticleId IdType="pubmed">9203684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, . . . Thompson KM (2015). Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. Journal of Infectious Diseases, 211(11), 1800&#x2013;1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, &amp; Thompson KM (2019). Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. Risk Analysis, 39(2), 402&#x2013;413, on-line October 408, 2018. doi:10.1111/risa.13214</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13214</ArticleId><ArticleId IdType="pmc">PMC7842182</ArticleId><ArticleId IdType="pubmed">30296340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, &amp; Thompson KM (2019). Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiology and Infection, 147, e295. doi:10.1017/S095026881900181X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S095026881900181X</ArticleId><ArticleId IdType="pmc">PMC6813650</ArticleId><ArticleId IdType="pubmed">31647050</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay MA, Collett MS, Hincks JM, Oberste MS, Pallansch MA, Okayasu H, . . . Dowdle WR (2014). Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. Journal of Infectious Diseases, 210(Suppl 1), S447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316866</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA, &amp; Vidor E. (2013). Poliovirus vaccine - Inactivated In Plotkin SA, Orenstein WA, &amp; Offit PA (Eds.), Vaccines (4th ed, pp. 573&#x2013;597). Philadelphia: WB Saunders.</Citation></Reference><Reference><Citation>Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. (2019). World population prospects;  The 2019 revision. . Retrieved from https://population.un.org/wpp/</Citation></Reference><Reference><Citation>Tangermann RH, Aylward RB, Hull HF, Nkowane BM, Everts H, &amp; Olive J-M (1999). Progress towards the eradication of poliomyelitis globally and in Africa, January 2000. M&#xe9;decine tropicale : revue du Corps de sant&#xe9; colonial, 59(4 Pt 2), 475&#x2013;482. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=10901850</Citation><ArticleIdList><ArticleId IdType="pubmed">10901850</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2006). Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis, 26(6), 1423&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184390</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2014). National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Review of Vaccines, 13(2), 221&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">24308581</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2015a). The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infectious Diseases, 15(376), doi:10.1186/s12879-12015-11116-12874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-12015-11116-12874</ArticleId><ArticleId IdType="pmc">PMC4574692</ArticleId><ArticleId IdType="pubmed">26382234</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2015b). Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infectious Diseases, 15(374), doi:10.1186/s12879-12015-11113-12877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-12015-11113-12877</ArticleId><ArticleId IdType="pmc">PMC4574397</ArticleId><ArticleId IdType="pubmed">26381878</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Kalkowska DA (2019). Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Review of Vaccines, 18(7), 725&#x2013;736. doi:10.1080/14760584.2019.1635463</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2019.1635463</ArticleId><ArticleId IdType="pmc">PMC6816497</ArticleId><ArticleId IdType="pubmed">31248293</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, &amp; Duintjer Tebbens RJ (2015). Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses Vaccine, 33(3), 1568&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907970</ArticleId><ArticleId IdType="pubmed">25701673</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Kim J-H, &amp; Cochi SL (2013). Preeradication vaccine policy options for poliovirus infection and disease control. Risk Analysis, 33(4), 516&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941951</ArticleId><ArticleId IdType="pubmed">23461599</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, . . . Gast C. (2019). The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet, 394(10193), 148&#x2013;158. doi:10.1016/s0140-6736(19)31279-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(19)31279-6</ArticleId><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>World Bank. (2019). World Bank list of economies (June 2019). Retrieved from http://databank.worldbank.org/data/download/site-content/CLASS.xls</Citation></Reference><Reference><Citation>World Health Assembly. (1988). Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Retrieved from http://www.who.int/csr/ihr/polioresolution4128en.pdf</Citation></Reference><Reference><Citation>World Health Organization. (1986). Expanded Programme on Immunization: EPI global overview (EPI/GAG/86/WP.1). Retrieved from Geneva:</Citation></Reference><Reference><Citation>World Health Organization. (1989). Poliomyelitis in 1986, 1987, and 1988 - Part 1. Weekly Epidemiological Record, 64(36), 273&#x2013;279.</Citation></Reference><Reference><Citation>World Health Organization. (1992). Expanded programme on immunization. Poliomyelitis in 1988, 1989, and 1990. Weekly Epidemiological Record, 67(16), 113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">1571237</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. (2014, October 20, 2013). World schedule as of 2013/October/20. Retrieved from http://www.who.int/immunization/monitoring_surveillance/data/en/</Citation></Reference><Reference><Citation>World Health Organization. (2015a). GAP III: WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use. Retrieved from http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf</Citation></Reference><Reference><Citation>World Health Organization. (2015b). Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations. Weekly Epidemiological Record, 90(50), 681&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">26685390</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. (2017). Meeting of the Strategic Advisory Group of Experts on immunization, April 2017 - conclusions and recommendations. Weekly Epidemiological Record, 92(22), 301&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. (2019a, May 21, 2019). Circulating vaccine-derived poliovirus. Retrieved from http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/</Citation></Reference><Reference><Citation>World Health Organization. (2019b, May 31, 2019). Polio reported cases. Retrieved from http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencepoliohtml</Citation></Reference><Reference><Citation>World Health Organization. (2019c). Two out of three wild poliovirus strains eradicated. Retrieved from https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated</Citation></Reference><Reference><Citation>World Health Organization. (2019d). WHO/UNICEF estimated coverage time series. Retrieved from http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html</Citation></Reference><Reference><Citation>World Health Organization. (2019e, May 28, 2019). Wild Poliovirus List. Retrieved from http://polioeradication.org/polio-today/polio-now/wild-poliovirus-list/</Citation></Reference><Reference><Citation>World Health Organization. (2020). Polio this week as of 9 January 2020. Retrieved from http://polioeradication.org/polio-today/polio-now/this-week/</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. (2013). Polio eradication and endgame Strategic Plan (2013&#x2013;2018). Geneva; 2013. Report No: WHO/POLIO/13.02. Retrieved from http://polioeradication.org/wpcontent/uploads/2016/07/PEESP_EN_A4.pdf</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. (2015). Polio eradication &amp; endgame: Midterm review July 2015. Geneva; 2015. Report No: WHO/POLIO/15.04. Retrieved from http://polioeradication.org/wp-content/uploads/2016/07/GPEI-MTR_July2015.pdf</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. (2019). Polio eradication and endgame strategic plan (2019&#x2013;2023). Geneva; 2019. Report No: WHO/POLIO/19.04. Retrieved from http://polioeradication.org/wp-content/uploads/2019/05/polio-endgame-strategy-2019-2023.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>